FDA lifts hold on NeoRx' STR (Skeletal Targeted Radiotherapy) programme:
This article was originally published in Clinica
The US FDA has lifted its hold on the further development of NeoRx' Skeletal Targeted Radiotherapy (STR) product for treating multiple myeloma, a cancer of the bone marrow. The agency's decision follows NeoRx's submission of data from a dosimetry study of STR, which had been requested by the FDA. The Seattle, Washington firm said that it intended to submit a phase III study protocol before the end of the second quarter of 2003 for review by the FDA. Three-year survival data on the STR phase I/II patients is expected to become available by the end of this year.
You may also be interested in...
As the first emergency use authorization is granted, Pfizer and Moderna stand accused of neglecting poorer nations as wealthy countries snap up early access to COVID-19 vaccines.
The FDA has released final guidance on “Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA” for the industry. The guidance brings clarity and aims at facilitating product development meetings between the FDA and the ANDA applicants for complex products.
By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.